NATCO Pharma Limited

NSEI:NATCOPHARM Stock Report

Market Cap: ₹248.3b

NATCO Pharma Future Growth

Future criteria checks 0/6

NATCO Pharma's revenue and earnings are forecast to decline at 5.1% and 20.1% per annum respectively. EPS is expected to decline by 19.2% per annum. Return on equity is forecast to be 17.7% in 3 years.

Key information

-20.1%

Earnings growth rate

-19.2%

EPS growth rate

Pharmaceuticals earnings growth17.6%
Revenue growth rate-5.1%
Future return on equity17.7%
Analyst coverage

Good

Last updated19 Dec 2024

Recent future growth updates

Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Nov 15
Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Recent updates

Investors Aren't Buying NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings

Dec 23
Investors Aren't Buying NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings

Is NATCO Pharma (NSE:NATCOPHARM) Using Too Much Debt?

Dec 08
Is NATCO Pharma (NSE:NATCOPHARM) Using Too Much Debt?

NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50

Nov 18
NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50

Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Nov 15
Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease

Oct 13
We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease

NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market

Aug 13
NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market

If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity

Jul 15
If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity

NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly

Jun 30
NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly

NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors

Jun 14
NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors

NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

May 30
NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

May 09
Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Apr 03
Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

Feb 21
NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

Feb 18
NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Feb 17
NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jan 25
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Jan 09
An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Dec 13
Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Sep 30
An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

Sep 12
Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Aug 12
NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jul 16
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Apr 20
NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

Dec 20
Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's

Aug 12
NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's

Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Jun 23
Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Earnings and Revenue Growth Forecasts

NSEI:NATCOPHARM - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202737,1518,96512,18815,1768
3/31/202655,29921,51817,71818,70010
3/31/202549,85520,09815,57115,55510
9/30/202445,63819,44812,83817,163N/A
6/30/202443,49016,365N/AN/AN/A
3/31/202440,02013,8838,52912,116N/A
12/31/202338,29812,778N/AN/AN/A
9/30/202335,63711,2745,2307,477N/A
6/30/202329,6308,152N/AN/AN/A
3/31/202327,0857,1536,4358,491N/A
12/31/202224,0743,890N/AN/AN/A
9/30/202224,7544,0715,5758,302N/A
6/30/202224,1914,154N/AN/AN/A
3/31/202219,4621,700-1,962465N/A
12/31/202116,8332,735N/AN/AN/A
9/30/202114,7802,558-2,457230N/A
6/30/202118,9903,931N/AN/AN/A
3/31/202120,5614,4094652,988N/A
12/31/202021,7564,820N/AN/AN/A
9/30/202023,0265,2381,5544,466N/A
6/30/202019,8614,404N/AN/AN/A
3/31/202019,1504,6085874,173N/A
12/31/201919,1594,875N/AN/AN/A
9/30/201919,9045,425-2,2001,600N/A
6/30/201920,4826,060N/AN/AN/A
3/31/201920,9456,4442,0716,688N/A
12/31/201824,0668,235N/AN/AN/A
9/30/201824,1218,815N/AN/AN/A
6/30/201822,9537,838N/AN/AN/A
3/31/201821,8486,962N/A4,636N/A
12/31/201719,8175,730N/AN/AN/A
9/30/201720,8955,506N/A4,985N/A
6/30/201721,6795,323N/AN/AN/A
3/31/201720,2024,860N/A3,458N/A
12/31/201617,6973,680N/AN/AN/A
9/30/201613,6922,113N/AN/AN/A
6/30/201612,4311,748N/AN/AN/A
3/31/201610,4231,549N/A1,122N/A
12/31/20159,3551,494N/AN/AN/A
9/30/20158,5491,266N/AN/AN/A
6/30/20158,3901,294N/AN/AN/A
3/31/20157,3051,293N/A927N/A
12/31/20148,0891,042N/AN/AN/A
9/30/20148,1081,199N/AN/AN/A
6/30/20147,6481,144N/AN/AN/A
3/31/20147,3891,027N/A1,440N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NATCOPHARM's earnings are forecast to decline over the next 3 years (-20.1% per year).

Earnings vs Market: NATCOPHARM's earnings are forecast to decline over the next 3 years (-20.1% per year).

High Growth Earnings: NATCOPHARM's earnings are forecast to decline over the next 3 years.

Revenue vs Market: NATCOPHARM's revenue is expected to decline over the next 3 years (-5.1% per year).

High Growth Revenue: NATCOPHARM's revenue is forecast to decline over the next 3 years (-5.1% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: NATCOPHARM's Return on Equity is forecast to be low in 3 years time (17.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 18:33
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NATCO Pharma Limited is covered by 26 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Sriraam RathiAnand Rathi Shares and Stock Brokers Limited
null nullAnand Rathi Shares and Stock Brokers Limited